← Back
$APRE All transactions

Aprea Therapeutics, Inc.

▲ BUY
5 / 10

Conviction

$ Value

$100K

Shares

123,915

Price

$1

Filed

Apr 1

Why this score? (5/10)
  • Open market buy (+3)
  • Director (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Peters Richard

Title

CIK

0001697628

Roles

Director

Transaction Details

Transaction Date

2026-03-31

Code

P

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

123,915

Footnotes

On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares. | The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation") | The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise.

Filing Info

Accession No.

0001104659-26-038518

Form Type

4

Issuer CIK

0001781983

Peters Richard's History

Date Ticker Type Value
2026-03-31 APRE $100K
2026-03-31 APRE
2025-06-30 KANT D
2025-06-30 KANT D $0
2025-06-30 KANT D $0
2025-06-25 KANT A $0
2025-06-23 KANT M $8K
2025-06-23 KANT F $1K
2025-06-23 KANT M $0
2025-06-05 APRE A $0

Other Insiders at APRE (90d)

Insider Bought Sold Last
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
$30K 2026-03-31
Gilad Oren
President/CEO
$25K 2026-01-30
Peters Richard 2026-03-31